In addition to people with a 7.5 percent risk for heart attacks or strokes, the 2013 guidelines – issued by the American College of Cardiology and the American Heart Association – advise statins for people with cardiovascular disease, for diabetics between ages 40 and 75, and for adults with high levels of “bad” low-density lipoprotein cholesterol.
One of the study stated that the new guidelines in a better way can determine who is truly at risk of a heart attack and should be given stations.
Treating more Americans with statins is worth the small risk of side-effects and would be cost-effective, a new report finds.
“Rather, the next phase of research should be directed at better ways of applying lifestyle and drug treatments to the millions, and possibly billions, worldwide who could potentially benefit from a cost-effective approach to primary prevention of atherosclerotic cardiovascular disease”. Critics say the calculator overestimates many patients’ risk and could lead to many people taking statins who would never have needed them.
The new guidelines, “have improved our ability to achieve the precision medicine goal of delivering the right treatments to the right patients”, study co-author Dr. Christopher O’Donnell of the U.S. National Heart, Lung, and Blood Institute, said in the news release.
“Statins are one of the most effective medicines, and this is reassuring that the new guidelines do work”, said Dr. Udo Hoffmann, lead author of the study and professor of radiology at Harvard Medical School. Researchers from Harvard’s T.H. One of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.
In an editorial published alongside the studies in JAMA on Tuesday, two influential cardiologists wrote that the new research should lay to rest debate over the metric used in the 2013 guidelines.
A study by Duke University researchers past year found that an additional 12.8 million USA adults could receive or become eligible for statin therapy under full implementation of the guidelines. So the new guidelines overall did a better job in discriminating between those who should and should not get statins. Under a more generous definition of cost-effectiveness, it would even be cost effective to give statins to people who have a greater than 3 percent risk of heart attack or stroke over the next 10 years, a scenario under which two thirds of adults 40 to 75 years old would be taking the drugs.
The new study has compared 2435 individuals with family history of heart conditions as they are related to the subjects of the Framingham Heart Study.
Other Harvard Chan School authors of the study included Stephen Sy and Sylvia Cho, researchers from the Center for Health Decision Science; Milton Weinstein, Henry J. Nissen says this population isn’t representative. The effect was deemed strongest for intermediate-risk participants. Like all such studies, the conclusions depend on the assumptions made and data chosen. And the 2013 guidelines here.
Doctors said the incidence of heart disease in the United States as well as deaths due to heart problems have come down because of wide-spread use of statins. One sign is that there was no big increase in prescriptions for statins in 2014, according to IMS Health, a health-care-information company.